The development of tyrosine kinase inhibitors able to counteract the function of BCR-ABL1 oncoprotein improved the survival of CML patients substantially [308,309], changing the natural course of this disease [309,310]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.